Related Experiment Videos
Acceleration of growth in two children treated with human growth hormone-releasing factor
Insights
Growth hormone-releasing factor (GHRF) treatment improved growth in children with growth hormone deficiency. This therapy restored growth hormone secretion, leading to accelerated linear growth and metabolic benefits.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
Background:
- Growth hormone deficiency (GHD) impairs linear growth in children.
- Current treatments aim to restore normal growth patterns.
Observation:
- Two GHD children received growth hormone-releasing factor (GHRF) via subcutaneous infusion for six months.
- Administration mimicked physiological growth hormone secretion patterns.
Findings:
- GHRF administration increased growth hormone secretion and accelerated linear growth in both children.
- Metabolic effects included nitrogen retention and increased urinary calcium excretion.
- One child showed significantly increased growth rates and elevated somatomedin C levels.
Implications:
- GHRF demonstrates potential in restoring growth hormone secretion and its anabolic effects in GHD.
- Further research is needed to determine the long-term efficacy and clinical utility of GHRF for GHD treatment.
Abstract:
Two growth hormone-deficient children were treated with growth hormone-releasing factor for six months. The pattern of administration--1 to 3 micrograms per kilogram of body weight, given subcutaneously over one minute every three hours by infusion pump--was chosen to simulate growth hormone secretion in normal children. During the first week of therapy, both children had evidence of the metabolic effects of increased growth hormone secretion--i.e., nitrogen retention, demonstrated by decreased nitrogen excretion (P less than 0.05), and increased urinary calcium excretion (P less than 0.01). Growth hormone secretion was increased after pulses of growth hormone-releasing factor during the entire six-month period, and growth was accelerated. One child grew at a rate of 7.1 cm per year, as compared with 4.6 cm per year before therapy; the other grew at a rate of 13.7 cm per year, as compared with 2.1 cm per year before therapy, and had increased serum levels of somatomedin C. Growth hormone--releasing factor can restore growth hormone secretion and its biologic effects, including an increase in nitrogen retention, an increase in serum somatomedin C, and acceleration of linear growth in children with growth hormone deficiency. It is premature to speculate how useful this agent will prove to be in the treatment of children with growth hormone deficiency.